Bruker (NASDAQ:BRKR) Given New $38.00 Price Target at Citigroup

Key Points

• Bruker's price target has been lowered by Citigroup from $40.00 to $38.00, indicating a potential upside of 9.45% from its previous close.
• In its recent earnings report, Bruker reported $0.32 EPS, missing the consensus estimate of $0.43 and showing a year-over-year revenue decline of 0.4%.
• The company currently holds a consensus rating of "Hold" among analysts, with six analysts rating it a hold and five assigning a buy rating.

Bruker (NASDAQ:BRKR - Get Free Report) had its price target dropped by equities research analysts at Citigroup from $40.00 to $38.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a "neutral" rating on the medical research company's stock. Citigroup's price objective points to a potential upside of 9.45% from the stock's previous close.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Bank of America decreased their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Stifel Nicolaus cut their price target on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Jefferies Financial Group dropped their target price on Bruker from $70.00 to $60.00 and set a "buy" rating for the company in a research note on Monday. Finally, Wells Fargo & Company decreased their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $53.10.

Bruker Price Performance

Shares of NASDAQ:BRKR traded down $3.27 during trading on Monday, hitting $34.72. 8,149,176 shares of the stock were exchanged, compared to its average volume of 2,385,735. The company has a market cap of $5.26 billion, a PE ratio of 66.77, a P/E/G ratio of 2.56 and a beta of 1.16. The company has a current ratio of 1.57, a quick ratio of 0.74 and a debt-to-equity ratio of 1.13. Bruker has a 12-month low of $32.07 and a 12-month high of $72.94. The company has a fifty day moving average price of $39.94 and a two-hundred day moving average price of $43.35.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.11). The business had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The firm's revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the company earned $0.52 EPS. On average, analysts forecast that Bruker will post 2.69 EPS for the current year.

Insider Buying and Selling

In other news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction on Friday, June 6th. The stock was bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the completion of the transaction, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 27.30% of the company's stock.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its position in shares of Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after acquiring an additional 196 shares during the last quarter. Insigneo Advisory Services LLC boosted its stake in Bruker by 4.7% during the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after acquiring an additional 218 shares during the last quarter. CGN Advisors LLC grew its holdings in Bruker by 1.4% during the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after acquiring an additional 296 shares in the last quarter. New York State Teachers Retirement System increased its position in shares of Bruker by 0.8% in the 1st quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company's stock worth $1,549,000 after purchasing an additional 300 shares during the last quarter. Finally, State of Michigan Retirement System raised its stake in shares of Bruker by 1.1% in the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company's stock valued at $1,106,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.